NO20044330L - Heterosykliske amider med alfa-4 intergrin-antagonistaktivitet - Google Patents
Heterosykliske amider med alfa-4 intergrin-antagonistaktivitetInfo
- Publication number
- NO20044330L NO20044330L NO20044330A NO20044330A NO20044330L NO 20044330 L NO20044330 L NO 20044330L NO 20044330 A NO20044330 A NO 20044330A NO 20044330 A NO20044330 A NO 20044330A NO 20044330 L NO20044330 L NO 20044330L
- Authority
- NO
- Norway
- Prior art keywords
- intergrin
- alpha
- antagonist activity
- heterocyclic amides
- amides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
- C07D207/48—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Oncology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200200805A ES2197003B1 (es) | 2002-04-08 | 2002-04-08 | Nuevos compuestos antagonistas de integrinas alfa. |
PCT/EP2003/003635 WO2003084984A1 (en) | 2002-04-08 | 2003-04-08 | Heterocyclic amides with alpha-4 integrin antagonist activity |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20044330L true NO20044330L (no) | 2004-10-28 |
Family
ID=28686084
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20044330A NO20044330L (no) | 2002-04-08 | 2004-10-12 | Heterosykliske amider med alfa-4 intergrin-antagonistaktivitet |
Country Status (12)
Country | Link |
---|---|
US (1) | US20050143391A1 (no) |
EP (1) | EP1495044A1 (no) |
JP (1) | JP2006506320A (no) |
KR (1) | KR20040094912A (no) |
AR (1) | AR039401A1 (no) |
AU (1) | AU2003233958A1 (no) |
BR (1) | BR0309120A (no) |
CA (1) | CA2477943A1 (no) |
ES (1) | ES2197003B1 (no) |
MX (1) | MXPA04008990A (no) |
NO (1) | NO20044330L (no) |
WO (1) | WO2003084984A1 (no) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101273614B1 (ko) * | 2004-07-08 | 2013-06-12 | 엘란 파마슈티칼스, 인크. | 중합체 부분을 포함하는 다가 vla―4 길항제 |
JP4980928B2 (ja) * | 2004-12-24 | 2012-07-18 | プロシディオン・リミテッド | Gタンパク質共役受容体(gpr116)作動薬および肥満および糖尿病治療のためのその使用 |
WO2006127584A1 (en) | 2005-05-20 | 2006-11-30 | Elan Pharmaceuticals, Inc. | Imidazolone phenylalanine derivatives as vla-4 antagonists |
JP2008542445A (ja) * | 2005-06-07 | 2008-11-27 | ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア | α2β1/GPIa−IIaインテグリン阻害剤 |
US8987306B2 (en) | 2005-06-07 | 2015-03-24 | The Trustees Of The University Of Pennsylvania | Inhibitors of integrin alpha2beta1 based on prolyl diaminopropionic acid scaffold |
KR20080025190A (ko) * | 2005-06-30 | 2008-03-19 | 프로시디온 리미티드 | G-단백질 결합된 수용체 효능제 |
TW200808723A (en) * | 2006-03-13 | 2008-02-16 | Univ California | Conformationally restricted urea inhibitors of soluble epoxide hydrolase |
CA2715527A1 (en) * | 2007-12-05 | 2009-06-11 | Michael Higginbottom | New compounds iv |
KR20100093104A (ko) * | 2007-12-05 | 2010-08-24 | 아스트라제네카 아베 | 항비만제로서의 피페라진 |
WO2009071668A2 (en) * | 2007-12-05 | 2009-06-11 | Biovitrum Ab (Publ) | Piperazine derivatives and their use as leptin receptor modulators |
WO2009124037A1 (en) * | 2008-03-31 | 2009-10-08 | Teva Pharmaceutical Industries Ltd. | Processes for preparing sunitinib and salts thereof |
WO2011014438A1 (en) | 2009-07-31 | 2011-02-03 | N.V. Organon | Fully human antibodies to btla |
WO2011084357A1 (en) | 2009-12-17 | 2011-07-14 | Schering Corporation | Modulation of pilr to treat immune disorders |
US10836720B2 (en) * | 2016-04-01 | 2020-11-17 | The Regents Of The University Of California | Inhibitors of integrin alpha 5 beta 1 and methods of use |
WO2018085552A1 (en) * | 2016-11-02 | 2018-05-11 | Saint Louis University | Integrin antagonists |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1001764A4 (en) * | 1997-05-29 | 2005-08-24 | Merck & Co Inc | Heterocyclic amides as cell adhesion inhibitors |
HUP0002495A3 (en) * | 1997-07-31 | 2001-01-29 | American Home Prod | Dipeptide and related compounds which inhibit leukocyte adhesion mediated by vla-4, pharmaceutical compositions comprising thereof and their use |
IL148014A0 (en) * | 1999-08-13 | 2002-09-12 | Biogen Inc | Cell adhesion inhibitors |
WO2001054690A1 (en) * | 2000-01-28 | 2001-08-02 | Biogen, Inc. | Pharmaceutical compositions containing anti-beta 1 integrin compounds and uses |
-
2002
- 2002-04-08 ES ES200200805A patent/ES2197003B1/es not_active Expired - Fee Related
-
2003
- 2003-04-08 MX MXPA04008990A patent/MXPA04008990A/es not_active Application Discontinuation
- 2003-04-08 KR KR10-2004-7015916A patent/KR20040094912A/ko not_active Application Discontinuation
- 2003-04-08 WO PCT/EP2003/003635 patent/WO2003084984A1/en active Application Filing
- 2003-04-08 EP EP03727281A patent/EP1495044A1/en not_active Withdrawn
- 2003-04-08 BR BR0309120-1A patent/BR0309120A/pt not_active IP Right Cessation
- 2003-04-08 AU AU2003233958A patent/AU2003233958A1/en not_active Abandoned
- 2003-04-08 CA CA002477943A patent/CA2477943A1/en not_active Abandoned
- 2003-04-08 AR ARP030101227A patent/AR039401A1/es not_active Application Discontinuation
- 2003-04-08 US US10/510,626 patent/US20050143391A1/en not_active Abandoned
- 2003-04-08 JP JP2003582179A patent/JP2006506320A/ja not_active Withdrawn
-
2004
- 2004-10-12 NO NO20044330A patent/NO20044330L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2003084984A8 (en) | 2003-12-11 |
AU2003233958A1 (en) | 2003-10-20 |
KR20040094912A (ko) | 2004-11-10 |
EP1495044A1 (en) | 2005-01-12 |
US20050143391A1 (en) | 2005-06-30 |
MXPA04008990A (es) | 2005-06-20 |
CA2477943A1 (en) | 2003-10-16 |
BR0309120A (pt) | 2005-01-11 |
JP2006506320A (ja) | 2006-02-23 |
WO2003084984A1 (en) | 2003-10-16 |
AR039401A1 (es) | 2005-02-16 |
ES2197003A1 (es) | 2003-12-16 |
ES2197003B1 (es) | 2005-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1583763T3 (da) | Benzoazolylpiperazinderivater med VR1-antagonistaktivitet | |
FR19C1072I2 (fr) | Derive de 2-acylaminothiazole et son sel | |
NL300784I2 (nl) | Ketorolac, of het trometamolzout ervan, en fenylefrine, of het hydrochloridezout ervan | |
DK1615889T3 (da) | Biphenylderivater med beta2-adrenergisk receptoragonist- og muscarinisk receptorantagonistaktivitet | |
DK1537078T3 (da) | Indoler med anti-diabetisk aktivitet | |
SE0200073L (sv) | Anordning med fördröjt minne | |
IS7599A (is) | Heterósýklískir kínasatálmar | |
IS8190A (is) | Ný P2X7 viðtakamótlyf og notkun þeirra | |
DE60331751D1 (de) | N-substituierte 2-oxodihydropyridinderivate als npy antagonisten | |
NO20044330L (no) | Heterosykliske amider med alfa-4 intergrin-antagonistaktivitet | |
DE602004019294D1 (de) | Tetrahydronaphthalin- und harnstoffderivate | |
IS8289A (is) | Bensimídasólón efnasambönd með 5-HT4 viðtaka gerandefnisvirkni | |
ATE499347T1 (de) | Amidderivate | |
NO20045064L (no) | Indol-, azaindol- og beslektede heterocykliske 4-alkenyl-piperidin-amider | |
ATE402154T1 (de) | Monohydrochloridsalz von 1-ä3-ä3-(4- chlorphenyl)propoxyüpropylüpiperidin | |
ATE423117T1 (de) | Heterocyclische 7-aminoalkylidenylchinolone und - naphthyridone | |
NO20055490D0 (no) | Risperidon monohydroklorid | |
NO20044033L (no) | Heterocykliske amidderivater med glykogen fosforylase inhibitorisk aktivitet | |
NO20052655D0 (no) | Sammensmeltede heterocykliske forbindelser | |
DK1652843T3 (da) | Amidderivater | |
ATE402700T1 (de) | Glycinamid-derivate als raf-kinase-hemmer | |
DE60332816D1 (de) | Nk1-antagonisten | |
NO20031332D0 (no) | Arylalkan-sulfonamider med endothelin-antagonistaktivitet | |
DE60324018D1 (de) | Agonisten | |
DK1575413T3 (da) | Dispenser med flere driftsformer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |